H6jo4z2qvF@Sense-ISeries-gaze-viewer.png
Sense Innovation’s TD I-Series is an eye gaze-enabled speech generating device purpose-built for speech rehabilitation, effective doctor-to-patient communication and eye tracking analysis.
"Sense Innovation" works exclusively with the eye-tracking device developer Tobii Dynavox as a local expert in Taiwan and is also capable of developing gaze-interaction software. Since 2015, Sense Innovation has been developing various types of eye-tracking softwares that encourage independence for people with disabilities to communicate and work on a computer via eye control. This year, Sense Innovation will showcase a new generation of eye gaze-enabled device, the "TD I-Series," at the Health Care Expo.

TD I-Series is a Windows-based all-in-one device that can be controlled completely with the eyes. It comes in 16-inch and 13-inch screen sizes and can be operable with either the eye control or the touch, or with a mouse or special switches. It includes the built-in eye-control AAC communication software known as TD Snap, enabling therapists to assist patients in eye-tracking speech therapy and making it easier for healthcare providers and aphasic patients to communicate.

We will showcase various mounts paired with the eye-control device on-site, offering a one-stop solution. Additionally, it will be the first public display of "The Eyeland"—an eye-tracking visual perception assessment software—and "The Sense AEye", an eye-tracking E-learning platform complete with teaching materials, tools and resources. Visitors are welcome to come by the booth (J1030) to learn more and try out the products.
2024-09-30
vlRJ4otK6v@1_YuGuard (1).jpg
YuGuard: Wireless and wearable arrhythmia identification patch
This product proposes a personal health guardian: heart health management system and platform with electrocardiogram (ECG) analysis and cardiac disease detection. The system includes front-end IoT-based hardware, a user interface on the smart device’s application (APP), a cloud database, and an AI platform for cardiac disease detection. The front-end IoT-based hardware, a wearable ECG patch with an analog front-end circuit and a Bluetooth module, can detect ECG signals. The APP on smart devices can not only display users’ real-time ECG signals but also label unusual signals instantly and reach real-time disease detection. These ECG signals will be uploaded to the cloud database. The cloud database is used to store each user’s ECG signals, which forms a big-data database for AI algorithms to detect cardiac disease. The classification categories of this model are based on the Advancement of Medical Instrumentation (AAMI) standard to fit the FDA/TFDA regulation and the average accuracy is more than 98.32%. The ECG dataset applied in this product is collected from patients in Tainan Hospital, Ministry of Health and Welfare. Moreover, signal verification was also performed by a cardiologist. The main advantages of this system are real-time monitoring, convenience for wear, and ease of use. This patch has been approved by TFDA (ID: 008050)( https://lmspiq.fda.gov.tw/web/MDPIQ/MDPIQ1000Result?licBaseId=1B7F2D5D-CDCC-4532-84BE-DCF74E65E687 ) with QMS2183. The service iOS APP (https://apps.apple.com/tw/app/yuguard/id6469807344 ) also provides anytime and anywhere arrhythmia monitoring. These can achieve home heart disease care, assist clinics in diagnosing heart diseases, and provide remote heart disease consultations, solving current medical dilemmas and achieving the goal of public health.
2024-09-13